Advanced bone age with rapid progression central precocious puberty
Conditions
Interventions
GnRHa plus long-acting growth hormone (LAGH) combination group:None
GnRHa monotherapy group:None
Sponsors
Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1.Girls meeting all three of the following criteria: (1). Diagnostic criteria for Rapid progression CPP or EFP: Rapid progression CPP: 1). Breast development before age 7.5 or menarche before age 10; 2). Pelvic ultrasound showing enlarged uterine and ovarian volumes, with multiple ovarian follicles >=4mm in diameter; 3). GnRH stimulation test shows LH peak >=5.0 U/L with LH/FSH peak ratio >=0.6 or basal LH >=3 U/L (stimulation test not required for menarcheal cases); 4). Bone age exceeds chronological age by >=1 year; 5). Accelerated linear growth with annual growth rate exceeding that of healthy age-matched children; 6). Rapid progression through pubertal stages, with short intervals (=4mm in diameter visible in the ovaries; 3). GnRH stimulation test shows LH peak >=5.0 U/L with LH/FSH peak ratio >=0.6 or basal LH >=3 U/L (stimulation test not required in menstruating individuals). 4). Bone age exceeds chronological age by >=1 year; 5). Accelerated linear growth with annual growth rate exceeding that of healthy age-matched children; 6). Rapid progression through pubertal stages, with short intervals (= 12 years;
Exclusion criteria
Exclusion criteria: 1.Exclude individuals meeting any of the following criteria: Organic central precocious puberty, such as central precocious puberty caused by various intracranial tumours; 2.Peripheral precocious puberty converted to central precocious puberty, such as McCune-Albright syndrome, congenital adrenal hyperplasia, etc.; 3.Presence of contraindications for growth hormone use, such as diabetes mellitus, active tumours, etc.; 4.Concurrent conditions causing growth impairment or short stature, such as growth hormone deficiency (GHD), small for gestational age (SGA), idiopathic short stature (ISS), Turner syndrome, hypothyroidism, or short stature associated with other severe chronic diseases (e.g., cardiac insufficiency, hepatic or renal insufficiency, chronic inflammatory bowel disease); 5. Receipt of any GnRHa or GH therapy within the six months preceding the baseline period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FAH SDS-PAH (pre-treatment) SDS; | — |
Secondary
| Measure | Time frame |
|---|---|
| ?PAH SDS (difference in PAH SDS before and after treatment);FAH-THt; | — |
Countries
China
Contacts
Public Contactye feng
Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology
Outcome results
None listed